Regeneron Genetics Center (RGC) has initiated an extensive proteomics research project analyzing nearly 200,000 Geisinger Health System patient samples using Thermo Fisher Scientific’s Olink Explore HT platform. This unprecedented scale aims to validate genetic hypotheses, identify novel biomarkers, and advance precision medicine initiatives. The platform’s scalability and specificity are critical for managing the complexities of this study, which builds on earlier genomic work conducted by RGC and Geisinger. This project complements parallel large-scale efforts like the UK Biobank Pharma Proteomics Project, solidifying Regeneron’s commitment to transformative scientific discovery.